Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review.

IF 3.1 Q2 PHARMACOLOGY & PHARMACY

Clinical Pharmacology : Advances and Applications Pub Date : 2021-12-06 eCollection Date: 2021-01-01 DOI:10.2147/CPAA.S331660

Irma Rahayu Latarissa, Melisa Intan Barliana, Anna Meiliana, Keri Lestari

{"title":"Potential of Quinine Sulfate for COVID-19 Treatment and Its Safety Profile: Review.","authors":"Irma Rahayu Latarissa, Melisa Intan Barliana, Anna Meiliana, Keri Lestari","doi":"10.2147/CPAA.S331660","DOIUrl":null,"url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) pandemic is currently the largest and most serious health crisis in the world. There is no definitive treatment for COVID-19. Vaccine administration has begun in various countries, but no vaccine is 100% effective. Some people are not protected after vaccination, and there are some groups of people who cannot be vaccinated therefore, research on COVID-19 treatment still needs to be done. Of the several drugs under study, chloroquine (CQ) and hydroxychloroquine (HCQ) are quite controversial, although they have good activity against SARS-CoV-2, both drugs have serious side effects. Indonesia with its wealth of natural ingredients has one potential compound, quinine sulfate (QS), which has the same structure and activity as CQ and HCQ and a better safety profile. The aim of this article was to review the potential of QS against the SARS-Cov-2 virus and outline its safety profile. We conclude that QS has the potential to be developed as a COVID-19 treatment with a better safety profile than that of CQ and HCQ.</p>","PeriodicalId":10406,"journal":{"name":"Clinical Pharmacology : Advances and Applications","volume":" ","pages":"225-234"},"PeriodicalIF":3.1000,"publicationDate":"2021-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3a/be/cpaa-13-225.PMC8665662.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology : Advances and Applications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CPAA.S331660","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 5

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is currently the largest and most serious health crisis in the world. There is no definitive treatment for COVID-19. Vaccine administration has begun in various countries, but no vaccine is 100% effective. Some people are not protected after vaccination, and there are some groups of people who cannot be vaccinated therefore, research on COVID-19 treatment still needs to be done. Of the several drugs under study, chloroquine (CQ) and hydroxychloroquine (HCQ) are quite controversial, although they have good activity against SARS-CoV-2, both drugs have serious side effects. Indonesia with its wealth of natural ingredients has one potential compound, quinine sulfate (QS), which has the same structure and activity as CQ and HCQ and a better safety profile. The aim of this article was to review the potential of QS against the SARS-Cov-2 virus and outline its safety profile. We conclude that QS has the potential to be developed as a COVID-19 treatment with a better safety profile than that of CQ and HCQ.

Abstract Image

查看原文本刊更多论文

硫酸奎宁治疗COVID-19的潜力及其安全性综述

2019冠状病毒病(COVID-19)大流行是目前世界上规模最大、最严重的健康危机。COVID-19没有明确的治疗方法。各国已开始接种疫苗，但没有一种疫苗是100%有效的。一些人在接种疫苗后没有得到保护，还有一些人群无法接种疫苗，因此，COVID-19的治疗研究仍需开展。在正在研究的几种药物中，氯喹(CQ)和羟氯喹(HCQ)颇具争议，尽管它们对SARS-CoV-2具有良好的活性，但两种药物都有严重的副作用。印度尼西亚拥有丰富的天然成分，有一种潜在的化合物，硫酸奎宁(QS)，它具有与CQ和HCQ相同的结构和活性，并且安全性更好。本文的目的是回顾QS对SARS-Cov-2病毒的潜力，并概述其安全性。我们的结论是，与CQ和HCQ相比，QS有潜力成为一种具有更好安全性的COVID-19治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊